# Eloralintide

A weekly injection that copies amylin, the fullness hormone released with insulin. Amylin drugs are being developed as a gentler alternative or partner to GLP-1.

Also called: LY3841136
Source page: https://peplogue.com/peptides/eloralintide/
Updated: 2026-10-22. Not medical advice.

## How it works

- Where it acts: Amylin receptors in the brainstem.
- What it changes: Stronger fullness signals and a slower-emptying stomach.
- What people notice: Less appetite and weight loss in phase 2 trials. Stomach side effects were reported.

## What the evidence shows

- **Weight loss in obesity**: Supported. Phase 2 (263 people, 48 weeks): 9.5% on the lowest dose to 20.1% on the highest, against 0.4% on placebo.

## Side effects and risks

- common: Mostly mild-to-moderate stomach symptoms and tiredness, more at higher doses.
- unknown: Longer-term safety is not known; phase 3 trials began around the end of 2025.

Who should avoid it: Anyone outside a clinical trial.

## How it has been given in trials

Weekly injection under the skin, 1 mg to 9 mg. There is no approved dose.

## Legal status

- United States: undefined
- European Union: undefined
- Spain: undefined. Investigational. No authorised product in Spain (not in CIMA). The only lawful route is a clinical trial; Spanish trial sites not verified.
- Germany: undefined. Not authorised in Germany. Only available in clinical trials; sale outside trials is unlawful under the AMG (§ 21, § 96). German trial sites not checked.
- France: undefined. Investigational drug, not authorised in France. Only lawful route is a trial; ANSM says peptides bought outside the official circuit are illegal.
- Italy: undefined. Investigational. Not authorised in the EU or Italy; only reachable through a clinical trial. Italian trial sites not checked.
- Netherlands: undefined. Experimental. No marketing authorisation in the Netherlands or EU; only in clinical trials. Offering it as a medicine without authorisation is illegal.
- United Kingdom: undefined
- Canada: undefined
- Australia: undefined

## Questions people ask

**What is eloralintide?**

A weekly injection from Eli Lilly that copies amylin, the fullness hormone released with insulin. Amylin drugs are being developed as a gentler alternative or partner to GLP-1.

**How much weight loss did eloralintide give?**

In a 263-person phase 2 trial over 48 weeks, loss ranged from 9.5% on the lowest dose to 20.1% on the highest, against 0.4% on placebo.

**What are the side effects of eloralintide?**

Mostly mild-to-moderate stomach symptoms and tiredness, more at higher doses. Longer-term safety is not known.

**When will eloralintide be available?**

It is not approved. Phase 3 trials began around the end of 2025 and are registered in obesity, diabetes and sleep apnea.

## Sources

- Eli Lilly: eloralintide phase 2 results (6 Nov 2025): https://investor.lilly.com/node/53246
- ClinicalTrials.gov: phase 3 trial NCT07321886: https://clinicaltrials.gov/study/NCT07321886